medRxiv preprint doi: https://doi.org/10.1101/2022.10.19.22281276; this version posted August 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon

- Sylvia Hartmann¹, Summaira Yasmeen¹, Benjamin M Jacobs², Spiros Denaxas^{3,4,5,6}, Munir
 Pirmohamed⁷, Eric R. Gamazon⁸, Mark J. Caulfield⁹, Genes & Health Research Team^{*}, Harry
 Hemingway^{3,4,6}, Maik Pietzner^{1,10,11,a}, Claudia Langenberg^{1,10,11,a}
- ⁵ ¹Computational Medicine, Berlin Institute of Health at Charité Universitätsmedizin Berlin, Berlin,
- 6 Germany

1

- 7 ²Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of
- 8 London, London, UK
- 9 ³Institute of Health Informatics, University College London, London, UK
- 10 ⁴Health Data Research UK, London, UK
- 11 ⁵British Heart Foundation Data Science Centre, London, UK
- 12 ⁶National Institute of Health Research University College London Hospitals Biomedical Research
- 13 Centre, London, UK
- ⁷Department of Pharmacology and Therapeutics, The Wolfson Centre for Personalised Medicine,
- 15 University Liverpool, Liverpool, UK, Liverpool, UK
- 16 ⁸Division of Genetic Medicine and Vanderbilt Genetics Institute, Vanderbilt University Medical
- 17 Center, Nashville, TN 37232, USA
- 18 ⁹William Harvey Research Institute, Queen Mary University of London, London, UK
- 19 ¹⁰MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
- 20 ¹¹ Precision Healthcare University Research Institute, Queen Mary University of London, London, UK
- 21 *A list of authors and their affiliations appears at the end of the paper
- 22 ^athese authors jointly supervised the work

23 Correspondence

- 24 Prof Claudia Langenberg (claudia.langenberg@bih-charite.de)
- 25 Dr Maik Pietzner (<u>maik.pietzner@bih-charite.de</u>)
- 26
- 27

29 Abstract

30 Raynaud's phenomenon (RP) is a common vasospastic disorder that causes severe pain and ulcers, but despite its high reported heritability, no causal genes have been robustly identified. We conducted a 31 genome-wide association study including 5,147 RP cases and 439,294 controls, based on diagnoses 32 33 from electronic health records, and identified three unreported genomic regions associated with the risk of RP (p<5×10⁻⁸). We prioritized ADRA2A (rs7090046, odds ratio (OR) per allele: 1.26; 95%-CI: 1.20-34 1.31; p<9.6x10⁻²⁷) and *IRX1* (rs12653958, OR: 1.17; 95%-CI: 1.12-1.22, p<4.8x10⁻¹³) as candidate causal 35 genes through integration of gene expression in disease relevant tissues. We further identified a likely 36 37 causal detrimental effect of low fasting glucose levels on RP risk (r_{G} =-0.21; p-value=2.3x10⁻³), and systematically highlighted drug repurposing opportunities, like the antidepressant mirtazapine. Our 38 39 results provide the first robust evidence for a strong genetic contribution to RP and highlight a so far underrated role of α_{2A} -adrenoreceptor signalling, encoded at ADRA2A, as a possible mechanism for 40 hypersensitivity to catecholamine-induced vasospasms. 41

42

44 Introduction

45 Raynaud's phenomenon (RP) is a common episodic, vasospastic disorder that affects 2-5% of the population and can severely affect an individual's quality of life by causing pain or even ulcers^{1–3}. RP 46 typically manifests with bi- or triphasic colour change in fingers and toes because of vasospasms in 47 48 arteriovenous anastomoses responsible for thermoregulation, that can be triggered by cold or emotional stress⁴. The causes for the more common form of primary RP are largely unknown^{4,5}, while 49 50 secondary RP is diagnosed as a consequence of connective tissue diseases, like systemic lupus 51 erythematosus (SLE) or systemic sclerosis (SSc), or triggered by use of drugs such as beta-blockers. 52 Management of RP is predominantly limited to the avoidance of triggers and evidence for medical treatment is generally weak. Repurposed vasodilators are the first line treatment if pharmacological 53 intervention is required due to progressive frequency of vasospastic attacks⁶, although only calcium 54 55 channel blockers have so far been shown to lead to a significant and reproducible reduction in the 56 frequency of vasospastic attacks⁷. However, use of systemic drugs for localized symptoms puts patients 57 at risk of generalised adverse effects, such as hypotension. While there are now trials investigating 58 local application of botulinum toxin to mitigate vasospastic effects with early promising results⁸, a better understanding of the underlying mechanisms is needed to develop safe and effective 59 60 treatments.

RP is highly heritable with estimates of 55-64% being reported^{9,10}, but previous candidate gene studies^{11,12}, like at serotonin receptors¹³, and an early, small (n=640 cases) genome-wide association study (GWAS)¹⁴ failed to provide evidence for any robustly associated regions or genes. In-depth investigation and integration of detailed information from primary and secondary healthcare records with genetic array data now provides the opportunity to study under-investigated diseases with diagnostic specificity at unprecedented scale.

Here, we present the so far largest GWAS for RP including 5,147 cases in the UK Biobank cohort¹⁵ and report two robust and strong (p<4.8x10⁻¹³) novel loci. We highlight two independent disease mechanisms supported by those loci that challenge and advance our current understanding of primary RP, with *ADRA2A* highlighting the role of α_{2A} -adrenoreceptors and *IRX1* as a putative regulator of vasodilation by altering prostaglandin and/or bradykinin responsiveness.

73 Results

74 We identified a total of 5,147 RP cases and 439,294 controls of European descent included in the 75 genetic analyses (Supplementary Tab. 1 and Supplementary Fig. 1) based on collation and evidence 76 of absence or presence of diagnostic codes from electronic health records (ICD-10 codes: I73.0, I73.00, 77 I73.01; CTV3/Read2: G730., G7300, G7301, G730z, XE0VQ), including 2,185 prevalent cases and 2,962 incident cases. We followed the recommendation by Wigley et al.⁴ to summarize all patients with a 78 79 relevant code under the term RP (Raynaud's phenomenon) rather than Raynaud's syndrome. Genome-wide association analysis 80 We identified a total of three genome-wide significant novel loci ($p<5.0\times10^{-8}$, minor allele frequency 81 (MAF) 14.3%-31.1%) associated with RP (Fig. 1 and Tab. 1; regional association plots in Supplementary 82 83 Fig. 2). Two of which met a more stringent significance threshold (p<1.0x10⁻⁹; Tab. 1), which we consider as tier 1 findings of which one had previously been shown to increase the risk of myocardial 84 85 infarction (rs12653958). All lead variants increased the risk for RP by ~20% per copy of the minor allele (Tab. 1) and resided in intergenic regions with no obvious functional variants in linkage disequilibrium 86 87 (LD; $r^2>0.6$) and were of low predicted impact (range: 0.36 - 3.41). Despite the established sex-

difference of RP, we did not find evidence that effects of any of the identified lead signals differed
between men and women (all p-values for interaction > 0.05; Supplementary Tab. 2). We estimated a

90 single nucleotide polymorphism (SNP)-based heritability on the liability scale of 7.7% (95%-CI: 4.8-

91 10.6%, p<2.4x10⁻⁷) with little evidence of genomic inflation (LD-score intercept 1.01; **Supplementary**

92 **Fig. 3**).

Tier	SNP	Chr	Position	Alleles	MAF	OR (95%-CI)	P value	Closest gene*
1	rs7090046	10	112860930	A/G	0.31	1.26 (1.20, 1.31)	9.58x10 ⁻²⁷	ADRA2A
1	rs12653958	5	4032849	A/G	0.30	1.16 (1.12, 1.22)	4.76x10 ⁻¹³	IRX1
2	rs3094013	6	31434366	G/A	0.14	1.17 (1.11, 1.24)	9.73x10 ⁻⁹	MICB

Table 1 Regional lead variants for the 8 loci significantly associated with Raynaud's phenomenon Tier = categorization whether genetic loci met a stringent Bonferroni threshold for significance (tier 1; $p<1.0x10^{-9}$) or the standard genome-wide significance threshold (tier 2; $p<5.0x10^{-8}$). N = 444,441, 5,147 cases and 439,294 controls. Chr = Chromosome; MAF = minor allele frequency; OR = odds ratio from logistic regression models; Alleles are given as effect allele/non-effect allele; *protein coding gene in italics

To evaluate whether genetic findings were specific for the development of RP or driven by associations
with diseases leading to secondary RP, we performed sensitivity analyses based on a more stringent
definition of primary RP (3,505 cases, 68.1%) that excluded potential secondary cases (see Methods).
Effect estimates for both tier 1 loci were highly consistent in size and direction (Supplementary Tab.
and remained genome-wide significant (p<1.4x10⁻¹² for both), indicating their potential role in the
idiopathic origin of primary RP, whereas the association within the MHC region was attenuated.





105 Figure 1 Manhattan plot of genome-wide association results for Raynaud's phenomenon (5,147 RP cases and 106 439,294 controls) Distribution of RP-associated single nucleotide polymorphisms across the genome, -log10(P-107 values) from logistic regression models are plotted for each variant. The grey dashed line indicates the genome-108 wide significant threshold at p=5x10⁻⁸. Regional sentinel variants at significant loci are highlighted with a diamond 109 and the closest gene, if any, is annotated.

110 ADRA2A and BBIP1 are likely effector genes at 10q25.2

The lead variant at this strongest locus, rs7090046, is located 24.1k bp downstream to ADRA2A and 111 112 181.9k bases downstream from BBIP1 (Fig. 2) and Bayesian fine-mapping identified a 95%-credible set of only 4 variants (see Methods), comprising rs7090046, rs1343449, rs1343451, and rs7084501 with 113 posterior inclusion probabilities (PIP) of 48.6%, 23.6%, 12.5% and 12.6% of the GWAS signal, 114 respectively. Variant rs1343449 is a reported gene expression quantitative trait locus (cis-eQTL) for 115 ADRA2A in artery tissue and statistical colocalization confirmed a shared genetic signal with RP with 116 117 high confidence (tibial artery, posterior probability (PP) > 96%; Fig. 2), with the RP risk-increasing A-118 allele of rs7090046 being associated with higher ADRA2A expression (beta=0.28, p=1.0x10⁻⁹). We also 119 observed evidence of colocalization with BBIP1 expression in the brain hippocampus and colon (PP> 120 98%; Fig. 2 and Supplementary Data 1), with the A-allele being associated with lower BBIP1 expression in brain hippocampus (beta=-0.37, p=9.1x10⁻⁹), raising the possibility that variants in the credible set 121 122 have pleiotropic, tissue-dependent effects in different directions.

123 ADRA2A encodes α_{2A} -adrenoreceptors, responsible for mediating response to stress in the central and peripheral autonomous nervous system¹⁶, and vasoconstriction in response to catecholamine release 124 125 in the small arteries and arterioles¹⁷. Our finding may imply that overstimulation or increased 126 expression of α_{2A} -adrenergic receptors contributes to the vasospastic effects characteristic of RP and 127 its symptoms, also in line with RP being an adverse effect of α_2 -adrenergic agonists such as clonidine^{4,18,19}. A possible role of *BBIP1*, in contrast, is less obvious. *BBIP1* encodes for a protein in the 128 129 BBSome complex, which is involved in the signalling from and to cilia.

130 Investigating thousands of other outcomes from the GWAS catalog²⁰ and the Open Targets platform²¹ 131 in addition to phenome-wide analyses of UK Biobank (p<10⁻⁶, see **Methods**), we observed no other 132 significant associations for rs7090046 or its proxies (r²>0.6), except for "specified peripheral vascular 133 disease" in UK Biobank (OR 1.18, p-value 4.5×10^{-11}), a non-specific code that comprises, among other 134 diseases, RP. These results suggest specificity of the mechanism underlying the genetic signal at 135 10q25.2 on RP.



136

Figure 2 Regional association plot at *ADRA2A/BBIP1*. Regional association plot for Raynaud's phenomenon (top), gene expression of *ADRA2A* in tibial artery (middle), and gene expression of *BBIP1* in hippocampus (bottom). *ADRA2A* and *BBIP1* have been prioritised as candidate causal genes based on statistical colocalization. Summary statistics from logistic regression models for RP are form the present study whereas summary statistics from linear regression models were obtained from GTEx v8²². Colouring of SNPs is based on linkage disequilibrium with the lead RP variant (rs7090046) at this locus. Numbers in brackets indicate posterior probabilities (PP) for a shared genetic signal with RP based on statistical colocalization.

144 *IRX1* is the likely effector gene at 5p15.33 and links to cardiovascular outcomes

145 We fine-mapped the second strongest signal at 5p15.33 to 24 variants with rs12653958 as the lead SNP with a PIP of 6.4%. The credible set also covered rs11748327 (PIP=4.7%) that has been reported 146 147 as a cis-eQTL for *IRX1* in skeletal muscle²². Statistical colocalization further confirmed a shared genetic signal between RP and IRX1 expression in skeletal muscle and tibial artery with high (PP=99%) and 148 moderate (PP=47%) confidence, respectively (Fig. 3). The RP-increasing effect-allele of rs11748327 was 149 150 associated with higher expression of *IRX1* in skeletal muscle (beta=0.57, p=1.1x10⁻²²) and tibial artery (beta=0.42, p=5.7x10⁻¹¹), suggesting that higher gene expression confers a higher risk for RP. *IRX1* 151 encodes for members of the homeobox containing genes which have been shown to be involved in 152 embryonic development and cellular differentiation²³. The lead variant, rs12653958, at this locus tags 153 a cluster of variants (r^2 =0.7-1.0) that has previously been reported to be associated with myocardial 154 infarction (MI)^{24,25} and coronary artery disease (CAD)²⁶ among East Asian populations and is further a 155 cross-ancestral signal for red blood cell phenotypes^{27,28}. In detail, the RP risk-increasing G-allele was 156 also associated with an increased risk for coronary artery disease (beta=-0.06; p< 1.8×10^{-8}) in data from 157 the BioBank Japan²⁶. The fact that this common variant (MAF_{EUR}=30.0%; MAF_{EAS}=22.3%) has not yet 158 been identified for MI or CAD in Europeans (p= 1.61x10⁻⁷) despite much larger sample sizes 159 (n=181,522)²⁹, might point to the possibility of a yet to be identified gene-environment interaction or 160 161 other characteristics distinct to the East Asian cohorts that account for this observation.



162

163 Figure 3 Regional association plot at IRX1. Regional association plot for Raynaud's phenomenon (top), gene 164 expression of IRX1 in skeletal muscle (middle), and gene expression of IRX1 in tibial artery (bottom). Summary 165 statistics from logistic regression models for RP are form the present study whereas summary statistics from linear regression models were obtained from GTEx v8²². Colouring of SNPs is based on linkage disequilibrium 166 167 with the lead RP variant (rs12653958) at this locus. Numbers in brackets indicate posterior probabilities (PP) for 168 a shared genetic signal with RP based on statistical colocalization.

169 RP in individuals of South Asian ancestry

We aimed to test for replication and transferability of our European-centric results in 401 RP cases of 170 British Bangladeshi and Pakistani ancestry from the Genes & Health cohort³⁰ (n=40,532), and observed 171 directionally concordant results (rs11748327; OR=1.16, 95%-CI=0.99-1.37, p-value=0.06; IRX1) for one 172 173 of the two strongest loci, while for the second one, rs7090046 (ADRA2A), the lead variant or suitable 174 genetic proxies were not available. While we were underpowered to replicate the remaining signals 175 due to low number of cases, we noted that the rare European variant rs7601792 (MAF=0.16%) was common among people of British Bangladeshi and Pakistani descent (MAF=12.7%) possibly indicating 176

177 an ancestry-specific signal. However, further studies with comparable numbers of RP cases are needed

to establish trans-ethnic and ethnic-specific risk variants for RP.

179 Genetic correlation between RP and other traits

180 We next tested for a shared genetic architecture (genetic correlation: r_G) between RP and known or 181 suspected risk factors and comorbidities with a vascular or immune origin/component like peripheral artery disease (PAD) or COVID-19 (Supplementary Data 2). We observed that possible causes or 182 183 related disorders for RP, like migraine ($r_{\rm G}$ = 0.21, p=9.0x10⁻³), PAD ($r_{\rm G}$ =0.38, p=2.1x10⁻³), or SLE ($r_{\rm G}$ =0.33 184 p=1.0x10⁻³) significantly (false discovery rate<5%) correlated when considering all RP patients, but 185 were strongly attenuated once we computed genetic correlations restricted to patients with primary RP (Supplementary Fig. 5, Supplementary Data 3). In contrast, other significant correlations persisted 186 187 (p<0.05) when we restricted genetic correlation analysis to results based on patients with primary RP (to which we refer to as robust in the following). This included significant inverse correlations with type 188 189 2 diabetes ($r_G = -0.14$, $p=2.7 \times 10^{-3}$), fasting glucose ($r_G = -0.21$, p=0 $p=2.3 \times 10^{-3}$), and a positive correlation 190 with HDL-cholesterol levels (r_{G} =0.13, p=9.2x10⁻⁴) (**Supplementary Fig. 5**).

191 To distinguish whether genetic correlations represent causal directions from versus towards RP or are 192 due to shared risk factors that likely act independently on RP and correlated traits, we performed latent causal variable analysis³¹ (see **Methods**). Out of a total of six phenotypes with evidence for significant 193 194 genetic correlations, only SLE (genetic causality proportion (GCP)=0.75; p< 1.7×10^{-4}) and fasting glucose (GCP=0.77; p<5.21x10⁻¹⁵) showed strong evidence for a causal genetic effect on RP risk, of which fasting 195 196 glucose but not SLE persisted in analyses considering only patients with primary RP (GCP=0.80; 197 p<1.3x10⁻¹⁶). These results indicate that low fasting glucose levels may causally increase the risk for RP, while frequent comorbidities of RP, like migraine, are likely explained by shared risk factors. 198

We then extended the targeted analysis by computing genetic correlations with 185 medical concepts - 'phecodes', to gain a more comprehensive view on possible diseases that share a genetic architecture with RP (see **Methods**; **Supplementary Data 4**). We observed 8 phecodes with significant, although moderate, genetic correlations with RP (**Supplementary Data 4**), of which only the significant genetic correlation with osteoporosis persisted when we restricted the analysis to patients with primary RP (r_{G} =0.35, p<8.7x10⁻⁵). However, none of the phenotypes showed evidence of a direct causal link towards or from RP in latent causal variant analysis (see **Methods**; **Supplementary Tab. 4**).

206 From genes to druggable targets

We finally searched for putative druggable targets for RP based on the identified loci by crossreferencing high-confidence gene assignments and functional interaction partners thereof³² in the Open Targets database²¹ (see **Methods**). While we identified no link for drugs with known (genetic) targets currently or previously in clinical trials for RP (e.g., phosphodiesterase inhibitors), we identified

a total of 211 drugs that target either directly (e.g., ADRA2A) or indirectly (e.g., PTGS2) gene products 211 212 identified in our study (Fig. 4 and Supplementary Data 5). More than 50 drugs had at least some affinity to α_{2A} -adrenergic receptors, although none did so specifically. Since we identified increased expression 213 214 of α_{2A} -adrenergic receptors as a possible disease-causing mechanism, partially selective antagonists, 215 such as the widely used antidepressant mirtazapine, might be promising candidates for repurposing. Among the drugs indirectly linked to RP-associated gene products, those counteracting 216 217 vasoconstriction or promoting vasodilation have greatest repurposing potential. For example, drugs 218 promoting prostaglandin (via PTGER1 but not PTGS2) or bradykinin signalling (via BDKRB2) such as dinoprostone or labradimil, respectively, might exert beneficial effects. However, the indirect nature 219 220 of the gene-drug-disease link for the latter (via altered IRX1 expression) requires further functional 221 follow-up to establish the precise underlying mechanism and effect directions.



222

Figure 4 Gene-Drug-Disease network for Raynaud's phenomenon. The network displays drug target information
 obtained from Open Targets²¹ for 1) Raynaud's Phenomenon (RP; blueish area), 2) genes associated with RP in
 the present study (yellow), and 3) interacting genes (white) based on functional work³².

226 Discussion

227 RP is a common but understudied disease with a high heritable component and identifying responsible 228 genes can advance our understanding of the aetiology and eventually guide the development of 229 treatment strategies. We identified, for the first time, two robust susceptibility loci. Through 230 integration with gene expression data, we demonstrated that the strongest locus likely acts via 231 increased expression of α_{2A} -adrenoreceptors in arterial tissue, augmenting the current concept of

predominantly α_{2C} -adrenoreceptors mediating the vasospasms seen in RP patients⁴. Increased expression of the transcription factor *IRX1* in muscle, and possibly arterial tissue, may further alter genes involved in prostaglandin and/or bradykinin sensing and production, providing a putative second novel mechanism identified in our genetic study. We lastly observed no strong evidence for a shared genetic architecture with suspected cardiovascular comorbidities for primary RP but did observe a novel detrimental effect of low fasting plasma glucose that might help to guide primary RP management.

239 Vasospastic attacks in RP have been repeatedly attributed to cold-induced activation of α_{2C} adrenoreceptors^{4,18,33,34}, but attacks also occur under thermoneutral conditions and selective, 240 241 pharmacological blocking of α_{2c} -adrenoreceptors did not mitigate symptoms in clinical trials³⁵. An 242 observation that aligns with the absence of an effect of a strong cis-eQTL for ADRA2C (rs35729104), 243 encoding for α_{2c} -adrenoreceptors, on RP risk (OR=1.02, p=0.29) in our study. We, in contrast, provide 244 genetically anchored evidence that α_{2A} -adrenoreceptors play an underrated role further supported by adverse drug reactions seen with α_{2A} -adrenoreceptor agonists (Fig. 5). More specifically, α_{2A} -245 246 adrenoreceptors mediate arterial vasoconstriction, thrombus stabilization, and hypothermic effects on body temperature^{36,37}. Our results are in line with a vasoconstrictive role of α_{2A} -adrenoreceptors 247 248 under thermoneutral conditions¹⁷ and subsequent RP risk and further support findings of a quantitively 249 stronger role of α_2 -adrenoreceptors compared to α_1 -adrenoreceptors during cold stress in RP patients^{38,39}. However, it might still be conceivable that both α_2 -adrenoreceptors act in a context-250 specific manner to induce vasospastic effects¹⁹ or another mechanism partakes in cold-induced RP 251 252 attacks, since pharmacological inhibition of α_2 -adrenergic receptors did blunt but not eliminate cold-253 induced vasoconstriction³⁸.

254



256

257 Figure 5 Scheme of the key finding. In people without Raynaud's phenomenon (RP) stimulation of $\alpha_{2A^{-}}$ and $\alpha_{2C^{-}}$ 258 adrenoreceptors contributes to vasoconstriction and lower blood flow. In patients with RP, blood flow is further 259 reduced due to overexpression of α_{2A} -adrenoreceptors creating a state of hypersensitivity to catecholamine-260 release. Created with BioRender.com

261 Currently, RP is treated depending on its severity. For mild cases, avoidance of triggers like cold or 262 emotional stress might be sufficient, but severe vasospastic attacks require pharmacological 263 interventions with calcium channel blockers as first line response⁶. However, overall effectiveness of calcium channel blockers⁵ or alternative vasodilatory medications such as angiotensin receptor 264 265 blockers, selective serotonin reuptake inhibitors, or phosphodiesterase-5 inhibitors is limited^{6.7}. 266 Negative findings that overall align well with the absence of genetic evidence for those targets in our 267 study. A staggering characteristic of the ADRA2A locus was the specificity in phenome-wide screens 268 and comprehensive database lookups, which indicated a RP-specific effect. Such a characteristic may 269 make the inhibition of the gene product, α_{2A} -adrenoreceptors, an interesting pharmacological target. 270 This does not rule out that systemically administered antagonists might exert adverse effects, but 271 inhibiting α_{2A} -adrenoreceptor activity in disease-relevant tissue, for example using topical solutions, 272 might provide a safe and effective treatment option. There are already approved medications that target α_2 -adrenoreceptor antagonistically like the widely prescribed antidepressant mirtazapine, but 273 they lack specificity for α_{2A} -adrenoreceptor³⁶ and case reports described the occurrence or worsening 274 275 of RP in two male patients under yohimbine treatment, another α_2 -adrenoreceptor antagonist, for erectile dysfunction^{40,41}. Clinical trials are needed to test whether treatment with mirtazapine, or 276 topical solutions thereof, can indeed mitigate vasospastic attacks in patients with primary RP, also 277 278 because an early study described relieved symptoms under methyldopa, a α_2 -adrenergic agonist⁴².

279 In addition to hypersensitivity to vasoconstrictive stimuli, missing vasodilation is the primary cause of 280 persistent vasospasms in RP. We identified overexpression of *IRX1*, the second strongest signal for RP, 281 in muscle cells and possibly tibial artery as a putative RP risk increasing mechanism. While little is

282 known about *IRX1* in general, a transfection study in gastric cancer cell lines identified several putative target genes of *IRX1* with a role in vasoconstriction and vasolidation⁴³. This included downregulation 283 284 of PTGER1, encoding the prostaglandin E2 receptor 1 (EP1) and upregulation of PTGS2, encoding 285 prostaglandin G/H synthase 2, as well as downregulation of BDKRB2, encoding bradykinin receptor B2. Prostaglandin E2 (PGE₂) can induce both vasodilation and vasoconstriction depending on receptor 286 binding, with binding to EP1 inducing vasoconstriction in smooth muscle cells^{44,45}. Downregulation of 287 BDKRB2 in endothelial and smooth muscle cells, in turn, may blunt the vasodilative function of 288 bradykinin⁴⁶, in line with observations in RP patients treated with bradykinin^{47,48}. A putative role of the 289 290 IRX1 locus in vasodilation/vasoconstriction might also explain its association with cardiovascular 291 disease as described among people of East Asian descent^{24–26}. Further experimental work will help clarify this, and might also help to refine the application of prostaglandin or bradykinin analogues, as 292 293 vasodilators in RP⁴.

294 Little is known about the causes of primary RP, and we provided evidence that genetic liability towards low fasting glucose levels increases RP risk. A putative mechanism, however, remains elusive and we 295 296 did not observe evidence that other metabolic risk factors were causally associated with RP risk, including BMI (Supplementary Data 3). Overexpression of α_{2A} -adrenoreceptors in pancreatic islet cells 297 298 has been postulated as a mechanism for diminished insulin secretion and postprandial hyperglycaemia among carriers of risk alleles in ADRA2A⁴⁹. However, the reported risk allele, rs553668, is only weakly 299 300 correlated (r^2 =0.15) with our RP lead signal at the same locus and the same applies for the more recently identified genome-wide significant finding⁵⁰. Although likely via distinct genetic variants, both 301 302 diseases seem to share overexpression of ADRA2A as a common, but tissue-specific, disease 303 mechanism, and it is unclear whether overexpression of ADRA2A in pancreatic beta-cells also 304 contributes to fasting glucose levels. Conversely, hypoglycaemia exerts profound changes on the 305 vasculature, including vasoconstriction via increased adrenal catecholamine release to maintain blood flow to the brain⁵¹, that may in turn exaggerate hypersensitivity to catecholamines of arteriovenous 306 307 anastomoses in fingers and toes. However, a drop in body temperature following hypoglycaemia is 308 caused by cutaneous vasodilation, which might itself be a trigger for vasospastic effects in RP patients. 309 Even a role of β -adrenergic receptors might be conceivable, since beta-blockers can cause both, hypoglycaemia⁵² and RP⁴. A pragmatic consequence for people at RP risk, or even RP patients, might 310 311 be to avoid episodes of low plasma glucose levels.

While we identify eight loci robustly associated with RP, we did not find support for genes highlighted by previous smaller scale and candidate gene studies. This included subthreshold findings from an earlier GWAS¹⁴ (*NOS1*, smallest p-value in *NOS1* region \pm 500kb (p_{min}) = 2.6x10⁻³) as well as candidate gene studies for serotonin 1B (*HTR1B*; p_{min}=6.8x10⁻⁴) and 1E (*HTR1E*; p_{min}=1.2x10⁻⁵) receptors and the beta subunit of the muscle acetylcholine receptor (*CHRNB1*; p_{min}=1.3x10⁻³)¹³. Our results therefore

highlight the need for large sample sizes, which are only now possible with the increased availabilityof electronic health record linkage.

319 Our study has limitations that need to be considered in the interpretation of the results. Firstly, we 320 defined patients with RP based on billing codes from medical records of various sources which might 321 have missed patients with milder presentations and suffers from potential misclassification if patient 322 symptoms have been wrongly assigned to RP, in particular in the presence of disease that cause RP as 323 a secondary phenomenon. However, our conservative sensitivity analysis, excluding all patients with 324 potential known causes of RP revealed congruent findings and the associated loci have a clear 325 biological link towards RP pathology. Secondly, our study was exclusively comprised of participants of 326 European descent and low case numbers and poor imputation quality of the main locus did not permit 327 robust analysis in other ancestries, which is needed to achieve fair representation of different 328 ancestries in genomic studies and may reveal additional findings. Thirdly, while we were able to 329 replicate the association between ADRA2A expression in tibial artery and risk of RP in a small, independent cohort (n=124 RP patients; OR=1.27; p = 0.0039) from the BioVU study⁵³, additional 330 331 efforts in large biobanks with linked primary care data are needed to further consolidate our findings. Finally, while we assign putative candidate genes at two loci, more work is needed to improve gene 332 333 assignment pipelines to elucidate possible mechanism at other loci including rare variants with strong 334 effect sizes.

Our results advance the understanding of RP pathology by shifting the focus from a merely coldinduced phenomenon to a clinical entity in its own right with a distinct genetic architecture. The identification of *ADRA2A* and *IRX1* as candidate causal genes will further inform the development and refinement of treatment strategies although more experimental work is needed.

340 Methods

341 United Kingdom Biobank (UKBB)

342 UK Biobank is a prospective cohort study from the UK which contains more than 500,000 volunteers between 40 and 69 years of age at inclusion. The study design, sample characteristics and genome-343 wide genotype data have been described in Sudow et al. and Bycroft et al.^{15,54}. The UKBB was approved 344 345 by the National Research Ethics Service Committee North West Multi-Centre Haydock and all study 346 procedures were performed in accordance with the World Medical Association Declaration of Helsinki ethical principles for medical research. We included 444,441 individuals in the GWAS for whom 347 inclusion criteria (given consent to further usage of the data, availability of genetic data and passed 348 349 quality control of genetic data) applied. Data from the UKBB were linked to death registries, hospital 350 episode statistics (HES) and primary care data.

351 RP case ascertainment

352 We used all available electronic health records, including primary (~45% of the population) and secondary care, death certificates as well as participant's self-report to define RP cases. We manually 353 354 curated relevant codes for RP based on the different coding systems used (ICD-10 codes: I73.0, I73.00, 355 I73.01; CTV3/Read2: G730., G7300, G7301, G730z, XE0VQ) and flagged the first occurrence of a related 356 code in the records of a participant as the incidence date. We compared the date of the very first record related to RP with the date of the baseline examination of the same participant to distinguish 357 358 between prevalent and incident RP. We followed the criteria from Wigley et al.⁴ to differentiate 359 between primary and secondary RP. In detail, we classified each RP case as 'secondary' when patients 360 were either under beta-blocker treatment or had been diagnosed with one of the following diseases 361 prior or at the same time of their RP diagnosis: arteriosclerosis, carpal tunnel syndrome, systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, Sjögren syndrome, hypothyroidism, 362 363 cryoglobulinemia, frostbite or other connective tissues diseases (Supplementary Data 6).

364 UKBB medication classification/ beta-blocker usage

365 During the baseline assessment self-reported regular medication use was recorded. Medication data 366 were categorized into 6,745 groups (Data field: 20003). 38 categories of the medication data were 367 identified manually to represent medication containing beta-blocker substances.

368 Demographic analysis

369 We performed χ^2 -tests and analysis of variance to test for statistically significant differences in 370 demographic characteristics between controls and RP cases using standard implementations in R 371 (v4.1.2).

372 Genotyping, quality control and participant selection

Details on genotyping for UKBB have been reported in detail by Bycroft et al.¹⁵. Briefly, we used data 373 374 from the 'v3' release of UKBB containing the full set of Haplotype Reference Consortium (HRC) and 375 1000 Genomes imputed variants. We applied recommended sample exclusions by UKBB including low 376 quality control values, sex mismatch, and heterozygosity outliers. We defined a subset of 'white 377 European' ancestry by clustering participants based on the first four genetic principal component derived from the genotyped data using a k-means clustering approach with k=5. We classified all 378 379 participants who belonged to the largest cluster and self-identified as of being 'white,' 'British', 'Any 380 other white background', or 'Irish' as 'white European'. After application of quality control criteria and 381 dropping participants who have withdrawn their consent, a total of 444,441 UKBB participants were 382 available for analysis with genotype and phenotype data.

We used only called or imputed genotypes and short insertions/deletions (here commonly referred to as SNPs for simplicity) with a minor allele frequency (MAF) > 0.001%, imputation score >0.4 for common (MAF \ge 0.5%) and >0.9 for rare (MAF<0.5%), within Hardy-Weinberg equilibrium (p_{HWE}>10⁻¹⁵), and minor allele count (MAC) > 10. This left us with 15,519,342 autosomal and X-chromosomal variants for statistical analysis. GRCh37 was used as reference genome assembly.

388 Genome-wide association study

389 We performed genome-wide association studies for RP and primary RP using REGENIE v2.2.4 via a twostep procedure to account for population structure as described in detail elsewhere⁵⁵. We used a set 390 of high-quality genotyped variants (MAF>1%, MAC>100, missingness <10%, p_{HWE}>10⁻¹⁵) in the first step 391 392 for individual trait predictions using the leave one chromosome out (LOCO) scheme. These predictions 393 were used in the second step as offset to run logistic regression models with saddle point 394 approximation to account for case/control imbalance and rare variant associations. Models were 395 adjusted for age, sex, genotyping batch, assessment centre, and the first ten genetic principal 396 components. We used a tier system to classify genome-wide significant loci. Given the absence of a 397 substantial replication cohort, we consider loci meeting a stringent p-value threshold of $p<1.0x10^{-9}$ as 398 robust findings (tier 1) and further considered loci meeting the standard genome-wide significance 399 threshold of $p < 5.0 \times 10^{-8}$ as strongly suggestive loci (tier 2).

400 LD score regression and genetic correlation to other common diseases

We tested for genomic inflation and calculated the SNP-based heritability using LD-score regression
 (LDSC v1.0.1)⁵⁶. We further used LDSC to compute genetic correlation between RP as well as primary
 RP and a set of 20 preselected traits and diseases (Supplementary Data 2). P-values were corrected
 for multiple testing by controlling the false-discovery rate at 5% according to the Benjamini-Hochberg
 procedure. To explore genetic correlation with other common diseases, we computed genetic

406 correlation to a set of 185 phecodes (see below; Supplementary Data 4) with at least 1% SNP-based
407 heritability derived from the UKBB.

408 Signal selection and fine-mapping

We used regional clumping (±500kb) to select independent genomic regions associated with RP
treating the extended MHC region as a whole (chr6:25.5-34.0Mb) and collapsed neighbouring regions
using BEDtools v1.5.

412 Within each region, apart from the MHC region, we performed statistical fine-mapping using "Sum of 413 single effects" model (SuSiE)⁵⁷ as implemented in the R package susieR (v.0.11.92). Briefly, SuSiE employs a Bayesian framework for variable selection in a multiple regression problem with the aim to 414 415 identify sets of independent variants each of which likely contains the true causally underlying genetic 416 variant. We implemented the workflow using default prior and parameter settings, apart from the 417 minimum absolute correlation, which we set to 0.1. Since SuSiE is implemented in a linear regression 418 framework, we used the GWAS summary statistics with a matching correlation matrix of dosage 419 genotypes instead of individual level data to implement fine-mapping (susie rss()) as recommended 420 by the authors⁵⁷. We computed the correlation matrix with LDstore v1.0.

421 Sex-specific SNP effect

We tested for a potential modulating effect of sex on SNP – RP association using an additional interaction term in logistic regression models with the same adjustment set as described above. We implemented this analysis in R v.4.1.2 using a set of 361,781 unrelated white European individuals.

425 Replication in East London Genes & Health

We performed a genome-wide association analysis of RP in the Genes & Health cohort of British individuals of South Asian ancestry. We defined RP status using electronic health records and using the same code list as for the European-ancestry cohort. We identified 401 RP cases and 40,131 controls with complete covariate and genetic data passing quality control³⁰ (mean age at recruitment: 41.2 yrs [s.d.D:14.2], 55.6% females).

431 Genotyping and quality control for Genes & Health is described in the Supplemental File 1. Briefly, 432 genotyping was done using the Illumina Infinium Global Screening Array v3 with additional multi-433 disease variants and imputed to TopMed version 3 using the Michigan Imputation Server. We used 434 REGENIE⁵⁵ for association testing with age, sex, age², and the first twenty genetic principal components 435 as covariates. We included only autosomal genetic variants with a MAF>1% (in this cohort), INFO score 436 >0.7 for imputed variants, $p_{HWE}>10^{-10}$, and missingness < 10%. To allow for comparison with the results 437 from UK Biobank, we used the liftOver tool (v.2.0) to map between hg19 and hg38.

438 eQTL mapping to tissues/ Functional annotation

- 439 We systematically tested for a shared genetic signal between RP loci and gene expression levels (eQTL) in 49 tissues from the GTEx project (v8)²². Briefly, we considered all protein coding genes or processed 440 transcripts encoded in a 1Mb window around RP loci and performed statistical colocalization⁵⁸ to test 441 442 for a shared genetic signal between RP and gene expression, as implemented in the R coloc package 443 (v.2.0). We only report RP loci – gene – tissue triplets with a posterior probability >80% for a shared 444 genetic signal as candidate causal genes. We adopted a recently recommended prior setting⁵⁹ with 445 p₁₂=5x10⁻⁶. All GTEx variant-gene cis-eQTL associations from each tissue were downloaded in January 446 2020 from https://console.cloud.google.com/storage/browser/gtex-resources.
- 447 We further used the PrediXcan software⁶⁰ to associate genetically predicted expression levels of 448 ADRA2A with the risk of RP in 124 RP cases and 16,965 controls of the BioVU cohort⁵³.
- 449 Phenome wide association studies and variant look-up
- 450 We performed phenome-wide association studies for each RP locus identified using the 451 comprehensive electronic health record linkage to generate a set of 1,448 'phecodes', from which we used 1,155 'phecodes' with a case number of more than 200. To generate phecode-based outcome 452 453 variables, we mapped ICD-10, ICD-9, Read version 2, Clinical Terms Version 3 (CTV3) terms codes from 454 self-report or medical health records, including cancer registry, death registry, hospitalization (e.g., 455 Hospital Episode Statistics for England), and primary care, to a set of summarized clinical entities called phecodes^{61,62}. For example, more than 90 ICD-10 codes can indicate participants with type 1 diabetes 456 457 that are here collectively summarized under the phecode 'type 1 diabetes'⁶³. We used any code that 458 was recorded, irrespective if it contributed to the primary cause of death or hospital admission, to 459 define phecodes. We adjusted all analyses for test centre to account for regional differences in coding 460 systems and case ascertainment. For each participant and phecode, we kept only the first entry irrespective of the original data set, generating a first occurrence data set. We dropped codes that 461 462 were before or in the participants' birth year to minimize coding errors from electronical health records. We implemented the same logistic regression framework used for sex-interaction testing 463 464 among unrelated individuals of White European ancestry. We applied a stringent Bonferroni correction 465 to account for multiple testing ($p < 3.7 \times 10^{-5}$).
- We further performed look-ups for all independent lead variants and proxies (r²>0.6) associated with RP in the OpenTargets database²¹ and the GWAS catalog²⁰ (<u>download: 27/04/2022</u>) to search for possibly previously reported traits and to establish novelty.

469 LCV analysis

470 To assess the evidence for a causal relationship between RP and each of the genetically correlated 471 phenotypes (Supplementary Data 3 and 4) we implemented a latent causal variable (LCV) model³¹. 472 The LCV model estimates a parameter termed genetic causality proportion (GCP). The values of GCP 473 ranges from -1 to 1, quantifying both magnitude and direction of genetic causality between two traits. 474 Briefly, the LCV model fits an unobserved latent variable, L, which mediates the genetic correlation 475 between two traits, and compares the correlation of each trait with L to estimate the GCP. A [GCP] 476 value of one indicates full genetic causality (suggestive for vertical pleiotropy) whereas a GCP value of 477 zero implies no evidence for genetic causality (suggesting that the genetic correlation between two 478 traits is likely to be mediated by horizontal pleiotropy or shared risk factors) and |GCP| < 1 indicates 479 partial genetic causality between two traits. Negative values of GCP estimate suggest that RP lies 480 downstream of the other trait and interventions on the other trait are likely to affect RP, while positive 481 GCP values indicate that the other trait lies downstream of RP. We implemented LCV analysis using 482 standard parameters with version 1.0. We used the same LD-scores as in the genetic correlation analysis and excluded the extended MHC regions from any calculations. We considered the number of 483 484 significant genetic correlation as testing burden for LCV results.

485 Drug target annotation

To identify putative druggable targets for RP and test for evidence for drugs already in clinical trials, we queried the Open Target database²¹ for all genes likely linked to GWAS loci (i.e., evidence from eQTL annotation or intronic). We augmented this gene list by functionally validated interaction partners from the SIGNOR network³² and retained all matching drugs for further investigation. We lastly manually screened all prioritized drugs to match mechanisms to signs and symptoms of RP.

491 Data availability

492 All individual level data is publicly available to bona fide researchers from the UK Biobank (https://www.ukbiobank.ac.uk/) or Genes & Health study (https://www.genesandhealth.org/). GWAS 493 494 summary statistics have been deposited at the GWAS Catalog (accession codes: GCST90271713 and 495 GCST90271714). Lookups and druggable targets were derived from the GWAS Catalog 496 https://www.ebi.ac.uk/gwas/ and the OpenTargets Genetics data base 497 (https://genetics.opentargets.org/).

498 Code availability

499 Associated code and scripts for the analysis are available on Github⁶⁴
500 (https://github.com/pietznerm/gwas_rp).

- 501
- 502

503 References

- 504 1. Hughes, M. et al. Prediction and impact of attacks of Raynaud'S phenomenon, as judged by 505 patient perception. Rheumatol. (United Kingdom) 54, 1443–1447 (2015).
- 506 2. De Angelis, R., Salaffi, F. & Grassi, W. Health-Related Quality of Life In Primary Raynaud 507 Phenomenon. JCR J. Clin. Rheumatol. 14, 206–210 (2008).
- 508 Fábián, B., Csiki, Z. & Bugán, A. Raynaud-szindrómás betegek életminőségének jellemzői. Orv. 3. 509 Hetil. 159, 636-641 (2018).
- 510 4. Wigley, F. M. & Flavahan, N. A. Raynaud's Phenomenon. N. Engl. J. Med. 375, 556–565 (2016).
- 511 5. Rirash, F. et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. 512 Cochrane Database Syst. Rev. 2017, (2017).
- 513 6. Belch, J. et al. ESVM guidelines – the diagnosis and management of Raynaud's phenomenon. 514 Vasa 46, 413–423 (2017).
- 515 Su, K. Y. C. et al. Vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst. 7. 516 Rev. 2021, (2021).
- 517 8. Ennis, D., Ahmad, Z., Anderson, M. A. & Johnson, S. R. Botulinum toxin in the management of 518 primary and secondary Raynaud's phenomenon. Best Pract. Res. Clin. Rheumatol. 35, 101684 519 (2021).
- 520 9. Cherkas, L. F. et al. Heritability of Raynaud's phenomenon and vascular responsiveness to 521 cold: A study of adult female twins. Arthritis Care Res. 57, 524–528 (2007).
- 522 Hur, Y. M. et al. Feeling of cold hands and feet is a highly heritable phenotype. Twin Res. Hum. 10. 523 Genet. 15, 166-169 (2012).
- 524 11. Smyth, A. E., Hughes, A. E., Bruce, I. N. & Bell, A. L. A case-control study of candidate 525 vasoactive mediator genes in primary Raynaud's phenomenon. Rheumatology 38, 1094–1098 526 (1999).
- 527 12. Shemirani, A. H. et al. Polymorphism of clotting factors in Hungarian patients with Raynaud's. Blood Coagul. Fibrinolysis 22, 56–59 (2011). 528
- 529 13. Susol, E. et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's 530 phenomenon. Arthritis Rheum. 43, 1641–1646 (2000).
- 531 14. Munir, S., Freidin, M. B., Brain, S. & Williams, F. M. K. Association of raynaud's phenomenon 532 with a polymorphism in the NOS1 gene. PLoS One 13, 1–8 (2018).
- 15. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 533 534 562, 203-209 (2018).
- 535 16. Zhang, X. & Sun, Y. The predictive role of adra2a rs1800544 and htr3b rs3758987 536 polymorphisms in motion sickness susceptibility. Int. J. Environ. Res. Public Health 18, (2021).
- 537 17. Chotani, M. A., Flavahan, S., Mitra, S., Daunt, D. & Flavahan, N. A. Silent α (2C)-adrenergic 538 receptors enable cold-induced vasoconstriction in cutaneous arteries. Am. J. Physiol. - Hear. Circ. Physiol. 278, 1075–1083 (2000). 539
- 540 18. Freedman, R. R., Sabharwal, S. C., Desai, N., Wenig, P. & Mayes, M. Increased α -Adrenergic 541 responsiveness in idiopathic raynaud's disease. Arthritis Rheum. 32, 61-65 (1989).
- 542 19. Freedman, R. R., Moten, M., Migaly, P. & Mayes, M. Cold-induced potentiation of α2-543 adrenergic vasoconstriction in primary raynaud's disease. Arthritis Rheum. 36, 685–690 544 (1993).

545 20. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
546 studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* 47, D1005–D1012
547 (2019).

- 548 21. Ochoa, D. *et al.* Open Targets Platform: Supporting systematic drug-target identification and 549 prioritisation. *Nucleic Acids Res.* **49**, D1302–D1310 (2021).
- 550 22. Consortium, G. The GTEx Consortium atlas of genetic regulatory effects across human tissues
 551 The GTEx Consortium* Downloaded from. (2021).
- 552 23. Küster, M. M. *et al.* Epigenetic inactivation of the tumor suppressor IRX1 occurs frequently in
 553 lung adenocarcinoma and its silencing is associated with impaired prognosis. *Cancers (Basel).*554 **12**, 1–20 (2020).
- 55524.Aoki, A. *et al.* SNPs on chromosome 5p15.3 associated with myocardial infarction in Japanese556population. J. Hum. Genet. 56, 47–51 (2011).
- 557 25. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes.
 558 *Nat. Genet.* 53, 1415–1424 (2021).
- Koyama, S. *et al.* Population-specific and trans-ancestry genome-wide analyses identify
 distinct and shared genetic risk loci for coronary artery disease. *Nat. Genet.* 52, 1169–1177
 (2020).
- 562 27. Vuckovic, D. *et al.* The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell* 182, 1214-1231.e11 (2020).
- 564 28. Chen, M. H. et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals
 565 from 5 Global Populations. Cell vol. 182 (2020).
- Aragam, K. G. *et al.* Discovery and systematic characterization of risk variants and genes for
 coronary artery disease in over a million participants. *medRxiv* 2021.05.24.21257377 (2021)
 doi:10.1101/2021.05.24.21257377.
- 569 30. Finer, S. *et al.* Cohort Profile: East London Genes & Health (ELGH), a community-based
 570 population genomics and health study in British Bangladeshi and British Pakistani people. *Int.*571 *J. Epidemiol.* 49, 20-21i (2020).
- 572 31. O'Connor, L. J. & Price, A. L. Distinguishing genetic correlation from causation across 52
 573 diseases and complex traits. *Nat. Genet.* 50, 1728–1734 (2018).
- 574 32. Licata, L. *et al.* SIGNOR 2.0, the SIGnaling Network Open Resource 2.0: 2019 update. *Nucleic*575 *Acids Res.* 48, D504–D510 (2020).
- 576 33. Edwards, J. M., Phinney, E. S., Taylor, L. M., Keenan, E. J. & Porter, J. M. α2-Adrenergic
 577 receptor levels in obstructive and spastic Raynaud's syndrome. *J. Vasc. Surg.* 5, 38–45 (1987).
- 578 34. Flavahan, N. A. A vascular mechanistic approach to understanding Raynaud phenomenon.
 579 Nat. Rev. Rheumatol. 11, 146–158 (2015).
- Herrick, A. L. *et al.* A double-blind, randomized, placebo-controlled crossover trial of the α2c adrenoceptor antagonist orm-12741 for prevention of cold-induced vasospasm in patients
 with systemic sclerosis. *Rheumatol. (United Kingdom)* 53, 948–952 (2014).
- 58336.Gyires, K., Zádori, Z. S., Török, T. & Mátyus, P. α2-Adrenoceptor subtypes-mediated584physiological, pharmacological actions. Neurochem. Int. 55, 447–453 (2009).
- 585 37. Hunter, J. C. *et al.* Assessment of the role of α2-adrenoceptor subtypes in the antinociceptive,
 586 sedative and hypothermic action of dexmedetomidine in transgenic mice. *Br. J. Pharmacol.*587 **122**, 1339–1344 (1997).

- S88 38. Cooke, J. P. *et al.* Role of digital artery adrenoceptors in Raynaud's disease. *Vasc. Med.* 2, 1–7
 S89 (1997).
- 590 39. Freedman, R. R., Baer, R. P. & Mayes, M. D. Blockade of vasospastic attacks by alpha 2591 adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. *Circulation*592 92, 1448–51 (1995).
- 59340.Johnson, S., Iazzetta, J. & Dewar, C. Severe Raynaud's Phenomenon with Yohimbine Therapy594for Erectile Dysfunction. J. Rheumatol. **30**, 2503–2505 (2003).
- 595 41. Sandler, B. & Aronson, P. Yohimbine-induced cutaneous drug eruption, progressive renal
 596 failure, and lupus-like syndrome. *Urology* 41, 343–345 (1993).
- 597 42. Varadi, D. P. & Lawrence, A. M. Suppression of Raynaud's Phenomenon by Methyldopa. *Arch.*598 *Intern. Med.* 124, 13–18 (1969).
- 599 43. Guo, X. *et al.* Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma. *Oncogene*600 29, 3908–20 (2010).
- 60144.Gomez, I., Foudi, N., Longrois, D. & Norel, X. The role of prostaglandin E2 in human vascular602inflammation. Prostaglandins Leukot. Essent. Fat. Acids 89, 55–63 (2013).
- 45. Ren, J., Karpinski, E. & Benishin, C. G. Prostaglandin E2 contracts vascular smooth muscle and
 inhibits potassium currents in vascular smooth muscle cells of rat tail artery. *J. Pharmacol. Exp. Ther.* 275, 710–9 (1995).
- 46. Marceau, F. & Regoli, D. Bradykinin receptor ligands: therapeutic perspectives. *Nat. Rev. Drug Discov.* 3, 845–52 (2004).
- Freedman, R. R., Girgis, R. & Mayes, M. D. Abnormal responses to endothelial agonists in
 Raynaud's phenomenon and scleroderma. *J. Rheumatol.* 28, 119–21 (2001).
- 48. Bedarida, G., Kim, D., Blaschke, T. F. & Hoffman, B. B. Venodilation in Raynaud's disease. *Lancet (London, England)* 342, 1451–4 (1993).
- 49. Rosengren, A. H. *et al.* Overexpression of alpha2A-adrenergic receptors contributes to type 2
 diabetes. *Science* 327, 217–20 (2010).
- 50. Vujkovic, M. *et al.* Discovery of 318 new risk loci for type 2 diabetes and related vascular
 outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat. Genet.* 52,
 680–691 (2020).
- 617 51. Morrison, S. F. Differential control of sympathetic outflow. *Am. J. Physiol. Regul. Integr. Comp.*618 *Physiol.* 281, R683-98 (2001).
- 619 52. Carnovale, C. *et al.* Beta-blocker-associated hypoglycaemia: New insights from a real-world
 620 pharmacovigilance study. *Br. J. Clin. Pharmacol.* 87, 3320–3331 (2021).
- 62153.Gamazon, E. R. *et al.* Using an atlas of gene regulation across 44 human tissues to inform622complex disease- and trait-associated variation. *Nat. Genet.* **50**, 956–967 (2018).
- 54. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide
 Range of Complex Diseases of Middle and Old Age. *PLoS Med.* **12**, 1–10 (2015).
- 55. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
 binary traits. *Nat. Genet.* 53, 1097–1103 (2021).
- 62756.Bulik-sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in628genome-wide association studies. *Nat. Publ. Gr.* **47**, (2015).

- 57. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
 selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Ser. B Stat. Methodol.* 82, 1273–1300 (2020).
- 632 58. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic
 633 Association Studies Using Summary Statistics. *PLoS Genet.* **10**, (2014).
- 634 59. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in colocalisation
 635 analyses. *PLoS Genet.* 16, 1–20 (2020).
- 636 60. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference 637 transcriptome data. **47**, (2015).
- 638 61. Denaxas, S. *et al.* Mapping the Read2/CTV3 controlled clinical terminologies to Phecodes in
 639 UK Biobank primary care electronic health records: implementation and evaluation. *AMIA* ...
 640 *Annu. Symp. proceedings. AMIA Symp.* 2021, 362–371 (2021).
- 64162.Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to phecodes: Workflow development and642initial evaluation. *JMIR Med. Informatics* **7**, 1–13 (2019).
- 643 63. Bastarache, L. Using Phecodes for Research with the Electronic Health Record: From PheWAS
 644 to PheRS. *Annu. Rev. Biomed. Data Sci.* 4, 1–19 (2021).
- 645 64. Hartmann, S. *et al.* ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon.
 646 *Zenodo* (2023) doi:10.5281/zenodo.8082736.

647

649 Acknowledgement

All research related to UK Biobank has been done under the application number 44448. Mu. P. wishes
to thank the MRC (MR/L006758/1, MR/V033867/1) and NIHR (NIHR202349) for support. This
collaboration is part of the National Institute For Health Barts Biomedical Research Centre portfolio.
BMJ is funded by a Medical Research Council (MRC) Clinical Research Training Fellowship (CRTF) jointly
supported by the UK MS Society (BMJ; grant reference MR/V028766/1), and by Barts Charity.

The authors acknowledge the Scientific Computing of the IT Division at the Charité -Universitätsmedizin Berlin for providing computational resources that have contributed to the research results reported in this paper (https://www.charite.de/en/research/research_support_services/research_infrastructure/science_it /#c30646061).

660 Genes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561), the Medical 661 Research Council (UK) (M009017, MR/X009777/1), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research 662 delivery support from the NHS National Institute for Health Research Clinical Research Network (North 663 664 Thames). Genes & Health is/has recently been funded by Alnylam Pharmaceuticals, Genomics PLC; and 665 a Life Sciences Industry Consortium of Astra Zeneca PLC, Bristol-Myers Squibb Company, 666 GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme 667 LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc.

668 We thank Social Action for Health, Centre of The Cell, members of our Community Advisory Group, 669 and staff who have recruited and collected data from volunteers. We thank the NIHR National 670 Biosample Centre (UK Biocentre), the Social Genetic & Developmental Psychiatry Centre (King's College 671 London), Wellcome Sanger Institute, and Broad Institute for sample processing, genotyping, 672 sequencing and variant annotation. We thank: Barts Health NHS Trust, NHS Clinical Commissioning 673 Groups (City and Hackney, Waltham Forest, Tower Hamlets, Newham, Redbridge, Havering, Barking 674 and Dagenham), East London NHS Foundation Trust, Bradford Teaching Hospitals NHS Foundation 675 Trust, Public Health England (especially David Wyllie), Discovery Data Service/Endeavour Health 676 Charitable Trust (especially David Stables), NHS Digital - for GDPR-compliant data sharing backed by 677 individual written informed consent. Most of all we thank all of the volunteers participating in Genes 678 & Health.

679 Author contributions

- 680 Conceptualization: Ma. P, CL
- 681 Data curation/Software: SH, SY, BMJ, SD, Ma. P
- 682 Formal Analysis: SH, SY, BMJ, EG, Ma. P

- 683 Methodology: SD, Ma. P
- 684 Visualization: SH, SY, Ma. P
- 685 Funding acquisition: CL, HH
- 686 Project administration: CL, HH
- 687 Supervision: Ma. P, CL
- 688 Writing original draft: SH, Ma. P, CL
- 689 Writing review & editing: SY, BMJ, SD, HH, Mu. P, MC
- 690

691 Competing Interests

692 Mu. P. has received partnership funding for the following: MRC Clinical Pharmacology Training Scheme

693 (co-funded by MRC and Roche, UCB, Eli Lilly and Novartis); and a PhD studentship jointly funded by

694 EPSRC and Astra Zeneca. Mu. P. also has unrestricted educational grant support for the UK

695 Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb. Mu. P. has developed

- an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of
- 697 the IMI Consortium ARDAT (www.ardat.org). None of the funding outlined above is related to the
- 698 current paper. None of the other authors have a competing interests.

700 Genes & Health Research Team

701 Jacobs Benjamin M²

²Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of

703 London, London, UK